Last week this drug was approved by NICE for use first line along with the TNF inhibitors adalimumab, etanercept, infliximab, certolizumab pegol and golimumab for patients with severe Rheumatoid Arthritis resistant to conventional treatment with 2 or more DMARDs (Disease …
No Comments. Continue Reading...We have recently updated the site to include new disease activity calculators for DAS28 and BASDAI (links are in the patient information tab). Look out for further calculators appearing soon (for example BVAS and BASFI).
I hope that in the …
No Comments. Continue Reading...